See more : Future First Technologies Ltd (FFT.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Synaptogenix, Inc. (SNPX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Synaptogenix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Smurfit Kappa Group Plc (SK3.IR) Income Statement Analysis – Financial Results
- Korea Steel Co., Ltd. (007280.KS) Income Statement Analysis – Financial Results
- Omax Autos Limited (OMAXAUTO.BO) Income Statement Analysis – Financial Results
- South Jersey Industries, Inc (SJIJ) Income Statement Analysis – Financial Results
- IRSA Propiedades Comerciales S.A. (IRCP) Income Statement Analysis – Financial Results
Synaptogenix, Inc. (SNPX)
About Synaptogenix, Inc.
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.35K | 5.71K | 4.97K | 4.87K | 4.39K | 3.00K |
| Gross Profit | -6.35K | -5.71K | -4.97K | -4.87K | -4.39K | -3.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.97M | 6.32M | 4.34M | 3.07M | 5.67M | 4.89M |
| General & Administrative | 6.34M | 9.81M | 8.28M | 8.09M | 9.84M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.34M | 9.81M | 8.28M | 8.09M | 9.84M | 6.26M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 28.36K | 0.00 | 0.00 |
| Operating Expenses | 8.31M | 16.13M | 12.62M | 11.16M | 15.51M | 11.15M |
| Cost & Expenses | 8.31M | 16.13M | 12.62M | 11.16M | 15.51M | 11.15M |
| Interest Income | 1.65M | 335.04K | 7.11K | 153.21K | 378.71K | 127.11K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.35K | 5.71K | 4.97K | 4.87K | 4.39K | 3.00K |
| EBITDA | -8.31M | -16.13M | -12.61M | -11.15M | -15.51M | -11.02M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.31M | -26.36M | -12.62M | -9.46M | -15.51M | -11.15M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.28M | 10.56M | 7.11K | -1.55M | 378.71K | 127.11K |
| Income Before Tax | -6.04M | -5.57M | -12.61M | -12.70M | -15.13M | -11.02M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -115.89K | -7.11K | 1.55M | -378.71K | 1.00 |
| Net Income | -6.04M | -5.46M | -12.60M | -14.25M | -14.76M | -11.02M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -29.56 | -0.78 | -2.51 | -11.33 | -2.48 | -46.33 |
| EPS Diluted | -29.56 | -0.78 | -2.51 | -11.33 | -2.48 | -46.33 |
| Weighted Avg Shares Out | 466.08K | 6.99M | 5.02M | 1.26M | 5.95M | 237.91K |
| Weighted Avg Shares Out (Dil) | 466.08K | 6.99M | 5.02M | 1.26M | 5.95M | 237.91K |
Best Penny Stocks To Buy Now? 7 Under $1 To Watch
Penny stocks priced under $1 per share have attracted a dedicated following among traders seeking massive returns. While penny stocks are inherently high-risk investments, the potential reward with these low-priced shares is exponentially higher compared to traditional blue chip stocks.
Best Penny Stocks To Buy Now? 3 Under $1 To Watch
Penny stocks, typically priced below $5, have become a popular choice for day traders due to their potential for rapid gains. These stocks can offer market-beating returns in a short period, making them attractive for those looking for quick profits.
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study
Positive changes in ALS gene expression and increased cellular viability met with statistical significance of p
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis
Study will evaluate drug's potential neuro-restorative mechanism(s) of action for improving synaptic health and cognitive function in MS patients NEW YORK , July 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative...
Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience
Phase 2 Bryostatin-1 Severe Cohort secondary and exploratory endpoint data selected by independent committee for presentation NEW YORK , July 13, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for...
Why Is Synaptogenix (SNPX) Stock Plummeting 70% Today?
Clinical-stage biopharmaceutical firm Synaptogenix (NASDAQ: SNPX ) demonstrated the harsh pitfalls associated with innovative medicine. Following the disclosure of disappointing results for its Phase 2 study involving the treatment of advanced Alzheimer's disease, SNPX stock dropped 70% on Friday morning,...
Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be
Synaptogenix has announced a readout of a Phase 2 randomized placebo-controlled trial in Alzheimer's disease for the current quarter. Preclinical work showed that its drug candidate Bryostatin-1 has some effect, and has a unique mechanism of action.
Synaptogenix Announces Corporate Update Conference Call
NEW YORK , July 21, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it will hold a corporate update conference call for investors. The call will take...
Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit
NEW YORK , March 29, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Company's President and Chief Scientific Officer, will present at...
Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum
NEW YORK , March 22, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Company's President and Chief Scientific Officer, will present...
Source: https://incomestatements.info
Category: Stock Reports